X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will be utilized for the preparation of Stalicla’s pioneering precision Autism Spectrum Disorder (ASD) Phase 2 trial evaluating STP1, a fixed dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide).
Lead Product(s): Ibudilast,Bumetanide
Therapeutic Area: Neurology Product Name: STP1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: SPRIM Global Investments
Deal Size: $17.4 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 16, 2024
Details:
STALICLA and Firefly will leverage their technological platforms including the DEPI and BNA platform respectively to further advance EEG validation in two upcoming Phase 2 clinical trials including STALICLA’s lead asset STP1, a tailored treatment candidate for ASD-Phenotype 1.
Lead Product(s): Ibudilast,Bumetanide
Therapeutic Area: Neurology Product Name: STP1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Firefly Neuroscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 27, 2023
Details:
The agreement covers the clinical development program of STP7 (mavoglurant) to treat patients diagnosed with cocaine use disorder (CUD), including a Phase 3 study.
Lead Product(s): Mavoglurant
Therapeutic Area: Psychiatry/Psychology Product Name: STP7
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 08, 2023
Details:
Under the terms of the agreement, STALICLA has acquired worldwide rights to AFQ056 (mavoglurant) for substance-use disorders, neurodevelopmental disorders, and other indications. Mavoglurant is a selective non allosteric metabotropic glutamate receptor 5 (mGluR5) antagonist.
Lead Product(s): Mavoglurant
Therapeutic Area: Psychiatry/Psychology Product Name: AFQ056
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $270.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 09, 2023
Details:
In addition to showing good safety and tolerability profile, and dose-dependent target engagement, STP1 treatment resulted in positive signals in clinical markers of neurological and behavioral function, including improved processing speed and crystallized cognition composite.
Lead Product(s): STP1
Therapeutic Area: Psychiatry/Psychology Product Name: STP1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
STP1 is a novel combination of compounds: a pan-PDE inhibitor with anti-inflammatory properties and a modulator of NKCC1, specifically targeting the biological dysregulations linked to ASD-Phen1.
Lead Product(s): STP1
Therapeutic Area: Psychiatry/Psychology Product Name: STP1
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
